FINWIRES · TerminalLIVE
FINWIRES

Archer Materials Advances Biosensor Medical Device Program to Beta Prototype Stage, Shares Jump 3%

By

Archer Materials (ASX:AXE) advanced to the next stage of product development via the construction of its beta prototype Biosensor platform suitable for preclinical validation, after its integrated alpha prototype medical device achieved clinical-grade potassium sensing accuracy, according to a Friday Australian bourse filing.

It plans to develop multiple versions of the beta prototype. The first beta prototype system is expected to become available for testing in the coming months. Early feasibility testing for monitoring lithium levels in blood is underway.

Additional optimization and validation are planned throughout the second half of the year, with the target of a fully optimized beta prototype for use in trials in 2027.

Its shares climbed 3% in recent trading on Friday.

Related Articles

Asia

Flight Centre Travel Group Completes AU$61.7 Million Sale of Pedal Group Stake

Flight Centre Travel Group (ASX:FLT) said it has formally completed the sale of its 47% shareholding in the Pedal Group cycle joint venture to the Turner Collective, receiving AU$61.7 million in proceeds, according to a Friday Australian bourse filing.The company said it will recognise a one-off accounting gain of about AU$15 million on the sale, in addition to boosting its cash reserves and allowing it to focus on growth initiatives in its core travel business.The company's shares fell 1% in recent Friday trade.

$ASX:FLT
Asia

Gpixel Changchun Microelectronics' IPO Stabilization Period Ends

Gpixel Changchun Microelectronics (HKG:3277) said the stabilization period of its initial public offering ended on Thursday, according to a same-day filing with the Hong Kong bourse.The Chinese semiconductor company said the overallotment option was fully exercised during the stabilization period for 9.79 million shares at HK$39.88 apiece.

$HKG:3277
Asia

ANZ Group Holdings Appoints UBS to Buy Back AU$248 Million in Shares to Neutralize DRP

ANZ Group Holdings (ASX:ANZ, NZE:ANZ) said it has appointed UBS Securities Australia to execute an on-market share purchase of about AU$248 million to satisfy its obligations under its dividend reinvestment plan (DRP) in relation to the 2026 interim dividend, according to a Friday Australian and New Zealand bourse filing.The bank said the DRP and bonus option plan (BOP) pricing period will run for 12 trading days, beginning Friday and finishing on June 1, with the on-market purchase of ANZ shares able to occur during the pricing period.ANZ will issue new shares to meet its DRP obligations if the on-market purchase cannot be completed for any reason, while new shares will also be issued to satisfy BOP obligations, the bank added.The bank's Australian shares rose almost 1% in recent Friday trade while its New Zealand shares gained almost 2%.

$ASX:ANZ$NZE:ANZ